Toward an evidence-based nonclinical road map for evaluating the efficacy of new tuberculosis (TB) drug regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo pharmacology workshop for TB drug development

Eric Nuermberger, Christine Sizemore, Klaus Romero, Debra Hanna

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.

Original languageEnglish (US)
Pages (from-to)1177-1182
Number of pages6
JournalAntimicrobial agents and chemotherapy
Volume60
Issue number3
DOIs
StatePublished - Mar 1 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Toward an evidence-based nonclinical road map for evaluating the efficacy of new tuberculosis (TB) drug regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo pharmacology workshop for TB drug development'. Together they form a unique fingerprint.

Cite this